Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial

Table 1

Demographics and baseline characteristics. Continuous variables are shown as mean ± SD.

	RD CsA(𝑛=99)	ST CsA(𝑛=100)
Recipient age (years)	49.8±11.77	49.4±10.44
Female recipient	25 (25.3%)	22 (22.0%)
White recipient	79 (79.8%)	77 (77.0%)
End stage disease leading to transplantation
Cardiomyopathy	49 (49.5%)	55 (55.0%)
Coronary artery disease	32 (32.3%)	30 (30.0%)
Other	18 (18.2%)	15 (15.0%)
Ventricular assist device	12 (12.1%)	8 (8.0%)
Panel reactive antibodies (%)
0%–10%	84 (84.5%)	87 (87.0%)
>10%	1 (1.0%)	0
Missing	14 (14.1%)	13 (13.0%)
Donor age (years)	35.3±13.9	35.5±11.9
Female donor	24 (24.2%)	35 (35.0%)
Cytomegalovirus D+/R−	23 (23.2%)	17 (17.0%)
Cold ischaemia time (hours) [mean ± SD]	2.8±1.1	3.2±1.2
Diabetes	31 (31.3%)	31 (31.0%)
Hypertension	45 (45.5%)	53 (53.0%)